Top Page
Biofrontera
(NASDAQ:BFRI)
Biofrontera (BFRI) vs. SPDR S&P 500 ETF (SPY)
Biofrontera Business Overview & Revenue Model
Biofrontera Earnings Call Summary
Biofrontera Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 37.16M | 37.30M | 34.07M | 28.67M | 24.10M | 18.85M |
| Gross Profit | 24.52M | 18.70M | 16.63M | 13.49M | 11.36M | 9.78M |
| EBITDA | -16.29M | -14.44M | -18.45M | 934.00K | -36.76M | -7.46M |
| Net Income | -17.57M | -17.76M | -20.13M | -640.00K | -37.71M | -10.99M |
Balance Sheet | ||||||
| Total Assets | 15.41M | 22.10M | 27.93M | 50.88M | 53.22M | 24.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.42M | 5.91M | 1.42M | 27.76M | 24.55M | 8.08M |
| Total Debt | 4.91M | 4.92M | 5.40M | 1.35M | 0.00 | 0.00 |
| Total Liabilities | 18.00M | 17.67M | 23.14M | 27.01M | 41.88M | 18.31M |
| Stockholders Equity | -2.58M | 4.43M | 4.79M | 23.88M | 11.34M | 5.83M |
Cash Flow | ||||||
| Free Cash Flow | -12.01M | -10.33M | -24.90M | -16.24M | -26.73M | -12.37M |
| Operating Cash Flow | -12.00M | -10.27M | -24.89M | -16.20M | -26.71M | -12.37M |
| Investing Cash Flow | -4.00K | -3.00K | 619.00K | -5.16M | -11.00K | 0.00 |
| Financing Cash Flow | 12.55M | 14.84M | 8.41M | 14.02M | 43.19M | 13.19M |
Biofrontera Technical Analysis
Biofrontera Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $13.54M | -29.32 | 0.27% | ― | 75.19% | ― | |
42 Neutral | $9.44M | ― | -1191.73% | ― | 5.11% | 19.78% | |
41 Neutral | $6.51M | ― | ― | ― | ― | ― | |
40 Underperform | $3.60M | ― | ― | ― | ― | ― | |
38 Underperform | $20.93M | -0.68 | -63.82% | ― | ― | ― |
Biofrontera Corporate Events
Biofrontera Inc. has announced that it has regained compliance with Nasdaq’s continued listing requirements under Listing Rules 5550(b)(1) and 5550(a)(2) as of November 4 and November 6, 2025, respectively. This compliance follows previous notifications of non-compliance due to the company’s stockholders’ equity and stock price falling below required thresholds earlier in 2025, impacting its market positioning and potentially averting delisting threats.
The most recent analyst rating on (BFRI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On November 6, 2025, Biofrontera Inc. completed the sale of its US license for Xepi® (ozenoxacin) Cream to Pelthos Therapeutics Inc. for up to $10 million. The transaction, which includes an initial $3 million payment and potential milestone payments, aims to strengthen Biofrontera’s cash position and support the growth of its photodynamic therapy platform, particularly the expansion of Ameluz® into additional indications. This strategic move is expected to fund the company to profitability and allows Biofrontera to focus on its core PDT franchise.
The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On October 20, 2025, Biofrontera Inc. finalized agreements with its former parent company, Biofrontera AG, to acquire all U.S. rights to Ameluz® and RhodoLED®. This strategic transaction involves a new earnout model replacing the previous transfer pricing model, which could impact the company’s revenue structure and market positioning in the U.S.
The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On October 23, 2025, Biofrontera Inc. announced the completion of its restructuring and asset purchase agreement with Biofrontera AG, acquiring all U.S. rights to Ameluz® and RhodoLED®, backed by an $11 million investment. This transaction, which includes a reduced earnout structure, is expected to enhance Biofrontera’s financial and operational profile by lowering costs and accelerating the company’s path to profitability. The deal also aligns long-term interests with Biofrontera AG through a 10% equity stake, and positions Biofrontera Inc. to expand Ameluz® growth and explore additional indications.
The most recent analyst rating on (BFRI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
On September 16, 2025, Biofrontera Inc. held a Special Meeting of Stockholders where several key proposals were approved. These included an amendment to the company’s certificate of incorporation to potentially conduct a reverse stock split to comply with Nasdaq listing requirements, and the issuance of common stock related to Series C and D Preferred Stock conversions. These decisions are aimed at strengthening Biofrontera’s market position and ensuring compliance with stock exchange regulations.
The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Biofrontera, Inc.’s recent earnings call paints a picture of a company experiencing a successful first half of 2025, characterized by record sales, strategic independence, and robust financial backing. Despite facing increased net losses and legal costs, the overall sentiment remains positive, buoyed by operational changes and promising growth prospects.
Biofrontera Inc. is a biopharmaceutical company focused on the development and commercialization of photodynamic therapy for dermatological conditions, primarily in the U.S. market.